#2 - Johnson & Johnson (NYSE:JNJ)
News about a Covid-19 vaccine will continue to attract investors. Yes, Johnson & Johnson (NYSE:JNJ) has a promising candidate that seems to check many of the boxes (i.e. single dose, long-term immunity, stores, and ships at refrigerator temperatures). And the company is conducting what is considered a “massive” 60,000 subject clinical trial. Should that go well, JNJ could be the leader in the clubhouse.
However, if you accept the premise that there may be more than one vaccine, then don’t sleep on Moderna (NYSE:MRNA). The company is attempting to bring the first successful messenger RNA (mRNA) vaccine licensed for human use. The science behind the vaccine is promising but unproven. Nevertheless, Moderna is receiving funds via Operation Warp Speed (OWS) and it’s a reasonable bet that they will be given a bite at the apple.
But even if they are shut out of the Covid-19 vaccine, getting a vaccine through clinical trials would be a proof of concept for their process. And that’s good news for the other candidates in its pipeline.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
More about Johnson & Johnson- Current Price
- $165.22
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 9 Buy Ratings, 9 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $171.33 (3.7% Upside)
